Dr Hillary Norton | SAPHNELO® (anifrolumab-fnia) LTE Safety Study

This video is intended for US healthcare professionals only.
Please see full Prescribing Information, including Patient Information: bit.ly/3xgURXR
Dr Hillary Norton reviews the clinical data and results from the long-term extension (LTE) safety study of SAPHNELO® (anifrolumab-fnia) and discusses how SAPHNELO may be right for your patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. Watch the video to learn more.
IMPORTANT PRODUCT INFORMATION
For adults with moderate to severe SLE on standard therapy. Not for severe active lupus nephritis or severe active CNS lupus. Serious, sometimes fatal infections have occurred. Increased risk of respiratory infections and herpes zoster. Avoid initiating during active infection. Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported. Avoid live or live-attenuated vaccines. Risk of malignancies unknown. Use not recommended with other biologic therapies. Infusion-related reactions may occur. Do not use if allergic to product components.